<DOC>
	<DOC>NCT00497731</DOC>
	<brief_summary>The primary purpose of this protocol is to investigate the safety and tolerability of AZD1152 when given as a continuous 2-hour infusion every week and every 2 weeks in patients with advanced solid malignancies.</brief_summary>
	<brief_title>AZD1152 in Patients With Advanced Solid Malignancies-Study 1</brief_title>
	<detailed_description />
	<criteria>Histological or cytological confirmation of a solid, malignant tumour At least measurable or non measurable site of disease as defined by modified RECIST criteria. Participation in an investigational drug study within 30 days prior to entry or who have not recovered from the effects of an investigational study drug Treatment with radiotherapy/chemotherapy with 4 weeks of first dose Recent major surgery within 4 weeks prior to entry to the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>Advanced solid tumors</keyword>
</DOC>